Gold Nanoparticle Contrast Agents in Mammography: A Feasibility Study
Abstract
The successful translation of molecular imaging to mammography and digital breast tomosynthesis would allow clinical molecular imaging of the breast. This is a potentially more sensitive approach to early breast cancer detection, especially in women at high risk. Bioconjugated gold (Au) nanoparticle (NP) imaging agents, used in conjunction with digital mammography and breast tomosynthesis, should provide improved lesion conspicuity. We are studying the feasibility of mammographic molecular imaging through in vitro mock tumor studies of Herceptin conjugated to Au-NP. Au-NP are exceptionally attenuating at mammographic energies; even very low concentrations are theoretically detectable. The primary aim of this study is to prove that Au-NP can act as a viable mammographic contrast agent. To date, we have synthesized bioconjugated HER2/neu Au-NP. Two breast cancer cell-lines have been established: BT-474 over-expresses HER2, while MDA-MB-468 is HER2 negative. We are currently measuring cellular affinity. In the near future, we will be ready to produce cell pellets that can be imaged by digital mammography and digital breast tomosynthesis to test for adequate contrast enhancement, both conventionally and using dual-energy subtraction methods. These data will be sufficient to determine whether mammography molecular imaging agents are feasible.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2007
- Accession Number
- ADA493737
Entities
People
- Andrew D. Maidment
Organizations
- University of Pennsylvania